Travere rises on co's marketing application for kidney disease drug

Shares of biopharma firm Travere Therapeutics TVTX.O rise 3.5% to $20.42

TVTX says it submitted a marketing application to the U.S. FDA for co's drug, Filspari, for treatment of a rare kidney scarring disease called focal segmental glomerulosclerosis

Co expects to receive regulatory decision in Q2

Filspari is currently approved to slow decline in kidney function in adults with immunoglobulin A nephropathy, a leading cause of kidney failure

Up to last close, TVTX has more than doubled in the past 12 months